ArticleJournal of virology2025
Functional and structural insights into HCMV terminase accessory proteins pUL77 and pUL93.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human cytomegalovirus (HCMV) is a significant cause of morbidity and mortality in immunocompromised and congenitally infected patients. Current antiviral therapies, primarily targeting the viral DNA polymerase, are limited by toxicity and resistance, underscoring the need for novel therapeutic strategies. Letermovir (LTV), which targets the viral terminase complex (pUL56-pUL89-pUL51), has improved prophylaxis in transplant recipients, but resistance mutations have already emerged. This complex is responsible for cleaving and packaging the viral genome into neo-formed capsids in close interaction with several other proteins. This study focuses on two essential terminase-associated proteins, pUL77 and pUL93, investigating their natural polymorphism, mutations arising under LTV prophylaxis, and the functional relevance of their putative nuclear localization signals (NLS). Sequence alignments across 18 herpesviruses revealed conserved and variable regions in both proteins. New mutations emerging in patients treated with LTV did not confer resistance, but the pUL77 R43C mutation, when present with pUL56 C325F, significantly reduces LTV resistance compared to C325F alone. In addition, nuclear localization motifs were assessed in the viral replication context and in autonomous cell production after plasmid transfection and revealed motifs essential for viral replication: IMPORTANCE: Human cytomegalovirus (HCMV) remains a significant health concern, particularly for immunocompromised individuals and in cases of congenital infection. The emergence of resistance to current antivirals targeting viral polymerase has necessitated the development of novel therapeutic approaches. Letermovir, which targets the HCMV terminase complex, represents a promising alternative. However, a deeper understanding of the virus's structural components and their interactions is crucial for identifying new potential drug targets. Here, we focused on two proteins, pUL77 and pUL93, which are associated with the viral capsid and interact with the terminase complex. By analyzing their polymorphism, structure, and functional motifs, we identified essential nuclear localization motifs and conserved regions in these proteins, providing valuable insights for the development of innovative anti-HCMV strategies, such as inhibitory peptides, which could complement existing treatments and address the ongoing challenge of antiviral resistance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.